Form D · Biotechnology

SEngine Precision Medicine, Inc.

Seattle, WA · CIK 0001752445

Offering snapshot reported Mar 10, 2023 · SEC filing

Reported sold
$600K
Offering amount: $3.58M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 24, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 10, 2023Initial$600,000No comparison2SEC filing
Oct 9, 2019Amendment$8,645,984$7,925,984vs Sep 12, 201840SEC filing
Sep 12, 2018Initial$720,000No comparison8SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-475546
In addition to the issuance of convertible promissory notes, the Company issued warrants to purchase common stock. The consideration for the warrants, if any, will only be realized upon exercise of the warrants.

Source: Form D, filed Mar 10, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Elliott Burkland Director
Jesse Ferrer Director
Carla Grandori Director, Executive, Promoter
Lee Hartwell Director
Tony Hsu Executive
Christopher Kemp Executive, Promoter
Ulrich Mueller Executive
Tom Neary Executive
Pablo Prichard Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
401 Terry Ave N.
Seattle, WA, 98109